When you encounter a patient with chest pain and positive stress testing but non-obstructive coronary disease, think beyond the major epicardial vessels. This scenario points to dysfunction at the microvascular level.

Coronary microvascular dysfunction (CMD) is the correct diagnosis here. This patient demonstrates the classic triad: anginal symptoms with exertional triggers, objective evidence of ischemia (positive stress test with ST depression), and angiographically normal or near-normal coronary arteries. The 30-40% stenoses are hemodynamically insignificant and cannot explain her symptoms. CMD affects the small resistance vessels (<500 micrometers) that regulate coronary flow but aren't visible on angiography. Women are disproportionately affected, and symptoms often persist despite standard anti-anginal therapy.

Option A, Prinzmetal angina, involves coronary vasospasm but typically occurs at rest, not with exertion, and would show transient ST elevation rather than depression. Option B, esophageal spasm, wouldn't produce the characteristic lateral lead ST changes or positive exercise stress test findings. Option C, anxiety-related chest pain, is a diagnosis of exclusion that doesn't explain the objective ischemic changes on stress testing.

The key study tip for USMLE Step 3: When you see exertional chest pain with positive stress testing but normal coronaries, especially in middle-aged women, strongly consider microvascular dysfunction. This represents an important cause of "chest pain with normal coronaries" and requires different management approaches than typical coronary artery disease.

This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the obese patient with stable CAD who smokes and has elevated BP and LDL requires prioritized lifestyle changes to reduce cardiovascular risk. The correct choice reflects smoking cessation and adopting a Mediterranean-style diet, which addresses major modifiable risks and aligns with evidence-based guidelines for secondary prevention. A common distractor might suggest avoiding all exercise until repeat angiography, which is unnecessary for stable disease and discourages beneficial physical activity. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.

This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the obese patient with stable CAD consumes sugary beverages, needing dietary tweaks for weight and metabolic control. The correct choice reflects replacing sugary drinks with water and reducing refined carbs, which aids weight loss and aligns with guidelines. A common distractor might suggest adopting a no-carb diet with unlimited processed meats, which increases saturated fat and cardiovascular risk. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.

This question tests knowledge of chronic coronary artery disease management, focusing on appropriate risk modification and treatment strategies. Chronic coronary disease management involves optimizing medical therapy (such as antiplatelets, statins, beta-blockers) and lifestyle modifications (diet, exercise, smoking cessation) to prevent progression and complications. In this scenario, the patient with CAD, obesity, prediabetes, and limited activity needs to enhance exercise for risk reduction. The correct choice reflects increasing moderate aerobic activity to 150 minutes per week, which improves cardiovascular health and aligns with guidelines. A common distractor might suggest avoiding exercise, which is detrimental and contradicts recommendations for physical activity in stable CAD. To help students: Encourage reviewing the latest clinical guidelines and understanding the rationale behind recommendations. Practice applying guidelines to different clinical scenarios to enhance decision-making skills.

This patient has stable coronary artery disease and is experiencing an increase in anginal symptoms despite being on guideline-directed medical therapy (GDMT). The first-line treatment for angina is beta-blockers. Before adding a second agent or proceeding to invasive testing, the initial therapy should be optimized. The maximum recommended dose for metoprolol succinate is 400 mg daily, so his current dose of 100 mg can be safely increased. Titrating the beta-blocker to the maximally tolerated dose to control heart rate and symptoms is the most appropriate next step.

This patient requires anticoagulation for atrial fibrillation (CHA₂DS₂-VASc score of 6) and is >12 months post-PCI with drug-eluting stent. Current guidelines recommend dual therapy with oral anticoagulation plus single antiplatelet therapy rather than triple therapy to reduce bleeding risk while maintaining ischemic protection. Aspirin is preferred over clopidogrel for the single antiplatelet agent in this setting. Triple therapy (option A) significantly increases bleeding risk and is not recommended for long-term use. Anticoagulation monotherapy (option C) may be considered but combination therapy is more commonly recommended. Option D uses a less optimal antiplatelet choice.

Current guidelines do not recommend routine surveillance stress testing or anatomic imaging for asymptomatic patients with known stable CAD, including those post-revascularization (PCI or CABG). Such testing is not shown to improve outcomes and can lead to unnecessary downstream procedures and costs. Testing is reserved for patients who develop new or worsening symptoms. Since this patient is asymptomatic with a good functional capacity and her risk factors are well-managed, the most appropriate approach is to continue optimal medical therapy and clinical follow-up without further cardiac imaging.

This patient has statin intolerance and an LDL level above the goal of <70 mg/dL (and often <55 mg/dL in very high-risk patients like this one). While trying a different statin at a low dose (C) is a reasonable strategy for statin-associated muscle symptoms, the patient is currently unwilling to do so. Therefore, the next best step is to add a non-statin agent. Ezetimibe is the first-line non-statin agent recommended by guidelines to lower LDL cholesterol. Fenofibrate (B) primarily targets triglycerides and has limited LDL-lowering effects and no proven mortality benefit in this setting. Niacin (D) is no longer recommended for routine use due to side effects and lack of proven benefit on cardiovascular outcomes when added to a statin.

This patient has lifestyle-limiting angina despite being on maximal or near-maximal doses of two antianginal agents (beta-blocker and long-acting nitrate). His heart rate and blood pressure are at the lower limits of normal, limiting further dose titration of beta-blockers or nitrates, and making the addition of a calcium channel blocker (amlodipine) problematic due to potential hypotension. While adding ranolazine (B) is an option for medical therapy, the severity of his symptoms despite an aggressive medical regimen makes him a candidate for revascularization. Therefore, the most appropriate next step is to proceed with coronary angiography to define his coronary anatomy and assess options for percutaneous coronary intervention or coronary artery bypass grafting.

This patient requires urgent surgery less than one month after receiving a drug-eluting stent (DES), placing him at very high risk for stent thrombosis if antiplatelet therapy is interrupted. The ideal scenario is to postpone elective surgery for at least 6 months. However, this surgery is urgent. The current consensus for managing dual antiplatelet therapy (DAPT) in this high-risk situation is to continue aspirin throughout the perioperative period to provide some protection against stent thrombosis, while holding the P2Y12 inhibitor (ticagrelor) for a short period (3-5 days) to reduce surgical bleeding risk. Continuing both (A) poses a very high bleeding risk. Holding both (B) poses an unacceptably high risk of stent thrombosis. Bridging therapy (D) is complex, expensive, and its efficacy in this setting is not well established; holding aspirin is also incorrect.